FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
FibroBiologics Announces 2025 Annual Meeting of Stockholders